Is Your Compounding Pharmacy Ready to Sell?

Pull your complete FDA correspondence file and state pharmacy board disciplinary history. Any unresolved 483 observations, warning letters, or consent orders will either kill a deal or require significant purchase price concessions. Engage a pharmacy regulatory consultant to draft and document corrective action plans for any open items before you approach buyers.

PCAB (Pharmacy Compounding Accreditation Board) accreditation signals to buyers that your facility meets rigorous quality and compliance standards independently verified by a third party. If you are not yet accredited, begin the application process immediately — it typically takes 6–12 months and requires full USP 795, 797, and 800 alignment. If you are already accredited, confirm your renewal date and ensure it will not lapse during the sale process.

Compile a complete compliance binder that includes your written USP 795 non-sterile and USP 797 sterile compounding policies, your USP 800 hazardous drug handling program, beyond-use dating (BUD) justification documentation, and any third-party compliance assessments. Buyers and their due diligence teams will request all of this in the first week of formal review.

Gather all cleanroom ISO classification certifications, HVAC performance verification reports, laminar airflow workbench (LAW) and biological safety cabinet (BSC) certification records, and equipment calibration logs. These records must be current — most buyers will require recertification if any documents are more than 12 months old at the time of closing.

Confirm that your state pharmacy board license, DEA registration, and any specialty permits (e.g., veterinary compounding, out-of-state distribution) are current, in good standing, and transferable. In asset sale structures — the most common deal format for compounding pharmacies — the buyer will need to apply for new licenses, so understanding transferability timelines is critical for deal structuring.

Work with a CPA experienced in pharmacy transactions to compile three full years of profit and loss statements, balance sheets, and cash flow statements. Reviewed financials carry significantly more weight with buyers and SBA lenders than internally prepared statements. If you have only tax returns and QuickBooks reports, invest in a CPA review engagement — it typically costs $3,000–$8,000 and pays for itself many times over in buyer confidence.

SDE is the primary valuation metric for compounding pharmacies in the $1M–$5M revenue range. Work with your M&A advisor or CPA to normalize earnings by adding back owner compensation, personal expenses run through the business, one-time costs (e.g., equipment purchases, legal fees, remediation costs), and non-cash charges like depreciation. Every dollar of defensible SDE add-back is worth 3.5x–6x in enterprise value.

Prepare a three-year revenue breakdown showing the split between sterile and non-sterile compounding, your top therapeutic categories (e.g., HRT, pain management, veterinary, pediatric), and your payer mix (cash-pay vs. insurance reimbursement vs. workers' compensation). Buyers will model revenue sustainability and margin profiles separately for each segment, so presenting this analysis proactively signals operational sophistication.

If your pharmacy bills any insurance or PBM networks, pull your audit history and confirm no open recoupment demands or payer disputes exist. Third-party payer audits represent contingent liabilities that SBA lenders will flag and buyers will use to negotiate escrow holdbacks or purchase price reductions. Resolving these before going to market eliminates a common late-stage deal complication.

Identify any family members on payroll, personal vehicle expenses, health insurance premiums, retirement contributions, or real estate leases between the business and the owner. Document each item clearly with supporting schedules. Related-party transactions that are not disclosed and normalized upfront become negotiating leverage for buyers during due diligence.

Document every compounding workflow in writing: formulation master records, compounding logs, sterility testing protocols, BUD assignment procedures, and batch release processes. SOPs must be specific enough that a licensed pharmacist unfamiliar with your operation could execute them without additional guidance. Buyers will review SOP quality as a proxy for operational transferability and regulatory defensibility.

Implement and document a QA program that includes environmental monitoring logs, out-of-specification (OOS) investigation records, complaint handling procedures, and annual product review protocols. Buyers conducting regulatory due diligence will request these records to assess compliance culture and identify any hidden liability. A functioning QA program also positions the pharmacy favorably in the event of a post-closing state board inspection.

Create a prescriber relationship report that lists each referring provider, their specialty, years of relationship, annual referral volume, and the nature of the relationship (e.g., personal relationship with owner vs. clinical relationship with staff pharmacist). This analysis allows buyers to assess concentration risk and plan a transition strategy. Prescriber relationships that exist primarily with clinical staff rather than the owner are significantly more transferable.

Draft a plan for introducing a new owner to your top 10–20 referring providers. This could include co-attendance at continuing education events, joint clinical consultations, or formal introduction letters. Buyers will not pay full value for prescriber relationships that have no documented transition plan. In many compounding pharmacy deals, the seller's willingness to facilitate prescriber introductions is a key negotiating point.

Compile a complete vendor list including your active pharmaceutical ingredient (API) suppliers, compounding equipment vendors, testing laboratory relationships, and any group purchasing organization (GPO) memberships. Confirm that key supplier agreements are assignable or can be re-executed by a buyer. API supplier relationships with FDA-registered suppliers are a positive quality signal that buyers will specifically look for.

The single greatest deal risk in compounding pharmacy transactions is owner dependency as the sole pharmacist-in-charge (PIC). If no other licensed pharmacist can fulfill the PIC role, the business effectively cannot operate between closing and the buyer obtaining their own PIC designation — a period that can span 30–90 days. Identify a qualified staff pharmacist now, begin the cross-training process, and confirm their willingness to remain through and beyond the ownership transition.

Identify your two or three most operationally critical employees — typically your lead compounding technicians and senior pharmacy staff — and assess their likelihood of staying through and after a transaction. Consider implementing stay bonuses funded from sale proceeds, with payments contingent on remaining employed 90–180 days post-closing. Document these arrangements as part of your transition planning package.

Confirm that your key employees have signed confidentiality agreements and, where appropriate, non-solicitation agreements. Buyers will request these documents and may condition closing on their existence. Conversely, review any existing agreements for terms that could create post-closing obligations or limitations on the buyer's ability to restructure the team.

Pull current license verification for every pharmacist and pharmacy technician on staff. Confirm continuing education requirements are current, DEA registrations are active where applicable, and no staff member has any board disciplinary history. Buyers will independently verify licensure status, and any lapsed or flagged licenses will require explanation.

Compounding pharmacy transactions require an advisor who understands pharmacy licensure timelines, USP regulatory risk, SBA financing requirements for healthcare businesses, and how to position prescriber relationships as transferable assets. A generalist business broker will likely undervalue your pharmacy, attract unqualified buyers, and struggle to navigate regulatory due diligence. Expect advisor fees of 5–10% of transaction value for businesses in the $1M–$5M revenue range.

Work with your advisor to prepare a CIM that tells the story of your pharmacy's clinical expertise, regulatory compliance posture, prescriber relationships, and financial performance. The CIM should include a company overview, market positioning narrative, facility description with certifications, financial summaries with SDE adjustments, and a clearly articulated growth opportunity for the incoming buyer. In compounding pharmacy transactions, the quality of the CIM directly influences the caliber of first-round offers.

Clarify whether your pharmacy facility is owned or leased, and determine the optimal structure for the transaction. If owned, decide whether to include real estate in the sale or lease it back to the buyer — sale-leaseback structures can generate separate liquidity while simplifying SBA financing. If leased, confirm your lease has at least 3–5 years remaining and that the landlord will consent to assignment. Buyers and SBA lenders will not close without lease security.

Commission a third-party quality of earnings analysis from an accounting firm familiar with pharmacy transactions. A QoE report validates your SDE adjustments, identifies any revenue recognition issues, and surfaces financial risks before a buyer's due diligence team does. Sellers who present a clean QoE report proactively are able to defend their valuation with confidence and reduce the risk of post-LOI price renegotiation.

Understand the tax consequences of asset sale vs. stock sale structures, the impact of installment sale treatment on seller notes, and whether your pharmacy qualifies for any Section 1202 exclusions or state-specific tax incentives. For most compounding pharmacy owners, the after-tax proceeds differential between deal structures can range from $100,000 to $500,000+ depending on your cost basis and state of residency.